# ClinicalTrials.gov record NCT05891496

> PeptideScanner retained ClinicalTrials.gov record NCT05891496 at 2026-07-30T16:23:45.669Z. Its registry update date was 2026-02-24, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct05891496-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-02-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05891496-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct05891496-semaglutide-v1.json
- Content SHA-256: `be4a0a5e4e3e1fe7127101a152e1c03cfc2f445b543785b448a2c3b8aceecdbd`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT05891496 ([`ctg-observation-nct05891496-2026-02-24-4bc3500de94e`](#source-ctg-observation-nct05891496-2026-02-24-4bc3500de94e))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05891496 at 2026-07-30T16:23:45.669Z. Its registry update date was 2026-02-24, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05891496-2026-02-24-4bc3500de94e`](#source-ctg-observation-nct05891496-2026-02-24-4bc3500de94e))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05891496 at 2026-07-30T16:23:45.669Z. Its registry update date was 2026-02-24, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05891496-2026-02-24-4bc3500de94e`](#source-ctg-observation-nct05891496-2026-02-24-4bc3500de94e))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05891496-2026-02-24-4bc3500de94e`](#source-ctg-observation-nct05891496-2026-02-24-4bc3500de94e))

## Sources

<a id="source-ctg-observation-nct05891496-2026-02-24-4bc3500de94e"></a>
- **ClinicalTrials.gov record NCT05891496 · retained source version 2026-02-24:4bc3500de94ed672737c75e0a14bd84f571ae2e3cad553e5a1899c32ee52794e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05891496) (`ctg-observation-nct05891496-2026-02-24-4bc3500de94e`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05891496." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct05891496-semaglutide-v1.json SHA-256: be4a0a5e4e3e1fe7127101a152e1c03cfc2f445b543785b448a2c3b8aceecdbd.